Clinical Trial Search

Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…

Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants

Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants

Primary: SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort — 15; 3; 16; 18 Participants

Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants

Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant

Primary: Participants Enrolled — 36 Participants

Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg

Primary: Part A: Number of Participants With All Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Day 29 — 0; 3; 0; 0 Participants

Primary: Change From Baseline in Self-Reported Symptom Scores From Well-to-Sick State Through Day 56 — 0.065; 0.281; 0.036; 0.113 Scores on a scale — p=<.0001

Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants

Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio

Primary: Change From Baseline to Day 8 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Shedding — -2.88; -3.52; -3.75; -3.03 log10 copies/ml — p=0.4829

Primary: Number of Subjects That Are Alive Without Respiratory Failure at Day 29. — 17; 14 Participants

Primary: Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 32; 36; 37; 43 Participants

Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants

Primary: Percentage of Participants Alive and Without Respiratory Failure Through Day 28 — 86.4; 79.2 percentage of participants — p==0.599

Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants

Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale

Primary: Number of Serious Adverse Events Relative to Treatment Group — 1; 3; 0 participants

Primary: Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29 — 85.7; 87.5; 74.4 percentage of participants — p=0.2598

Primary: Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection — 12.2; 31.8; 89.6 events per 100 person years

Primary: Number of Participants With Positive Results on Both the Q-POC SARS-CoV-2 Assay and the RT-PCR Comparator Test — 130 Participants

Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants

Primary: Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1) — 4; 5; 9…

Primary: SARS-CoV-2 Infection — 4; 2 Participants

Primary: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 — 45 Unsolicited Adverse Events

Primary: Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points — 10.0; 10.0; 12.0 days — p=0.9561

Primary: Occurrence of Solicited Local AE Signs and Symptoms 7 Days Following the Vaccination — 10; 12; 10; 2 Participants

Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 95; 69; 72; 65 Participants